fluorodeoxyglucose f18 has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 2 (22.22) | 2.80 |
Authors | Studies |
---|---|
Allard, NAE; Blijlevens, NMA; Boss, M; Gotthardt, M; Hopman, MTE; Janssen, L; Lobeek, D; Schirris, TJJ; Swaans, GJA; Timmers, S | 1 |
Hirata, H; Io, K; Kitagawa, T; Nagai, K; Oka, T | 1 |
Cui, Z; Feng, X; Guan, H; Hu, W; Liu, X; Peng, J; Su, Z; Wang, W; Wang, Z; Wu, F; Wu, S; Yang, J; Zhao, C; Zhao, H | 1 |
Du, B; Hsu, B; Li, N; Li, X; Li, Y | 1 |
Aschoff, P; Häntschel, M; Lichy, M; Oksüz, M; Pfannenberg, C; Vogel, W; Werner, MK | 1 |
Kaya, B; Sari, O; Varoglu, E | 1 |
Alavi, A; Kumar, R; Takalkar, A; Xiu, Y; Yu, JQ; Zhuang, H | 1 |
Biesma, DH; Grutters, JC; Post, MC; Verzijlbergen, JF | 1 |
Inoue, H; Jinnouchi, S; Kukita, T; Matsumoto, T; Nakajo, M; Otsuka, M; Tanabe, H; Tateno, R | 1 |
9 other study(ies) available for fluorodeoxyglucose f18 and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Article | Year |
---|---|
Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia.
Topics: Blood Glucose; Cardiovascular Diseases; Fluorodeoxyglucose F18; Glucose; Glycogen; Humans; Hyperglycemia; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Tyrosine Kinase Inhibitors | 2023 |
[18F-fluorodeoxyglucose-positron emission tomography imaging before and after treatment of chronic-phase chronic myeloid leukemia with tyrosine kinase inhibitors].
Topics: Fluorodeoxyglucose F18; Fusion Proteins, bcr-abl; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors | 2020 |
Philadelphia chromosome-positive acute myeloid leukemia with masses and osteolytic lesions: finding of 18F-FDG PET/CT.
Topics: Bone Marrow; Fluorodeoxyglucose F18; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Osteolysis; Positron Emission Tomography Computed Tomography; Soft Tissue Neoplasms | 2017 |
18F-FDG hepatic superscan in a patient with chronic myeloid leukemia.
Topics: Fluorodeoxyglucose F18; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals | 2014 |
Integrated FDG-PET/CT for detection, therapy monitoring and follow-up of granulocytic sarcoma. Initial results.
Topics: Adult; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Retrospective Studies; Sarcoma, Myeloid; Tomography, X-Ray Computed; Young Adult | 2009 |
Chronic myeloid leukemia detected on FDG PET/CT imaging in a patient with renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2013 |
Diffuse bone marrow accumulation of FDG in a patient with chronic myeloid leukemia mimics hematopoietic cytokine-mediated FDG uptake on positron emission tomography.
Topics: Bone Marrow; Cytokines; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Positron-Emission Tomography | 2004 |
PET scintigraphy of etoposide-induced pulmonary toxicity.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Etoposide; Fluorodeoxyglucose F18; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Male; Positron-Emission Tomography; Radiopharmaceuticals; Rare Diseases | 2007 |
FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Treatment Outcome | 2007 |